A Phase I/II, Ascending Multi-Dose Study of BMS-663513, An Agonistic Anti-CD137 Monoclonal Antibody, Administered Every Three Weeks to Patients With Metastatic or Locally Advanced Solid Malignancies

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 01 Apr 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Urelumab (Primary)
Indications Solid tumours
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
Sponsors Bristol-Myers Squibb

18 Oct 2016 Results of integrated safety and preliminary pharmacodynamic data analysis from this and other two studies (n=346) published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
28 Jun 2012 Planned number of patients changed from 103 to 110 as reported by European Clinical Trials Database.
11 Aug 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com